Valeant Pharmaceuticals International Stock Probability Of Bankruptcy
Valeant Pharmaceuticals' likelihood of distress is above 80% at this time. It has very high risk of going through financial hardship in the upcoming years. Probability of bankruptcy shows the probability of financial torment over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the Valeant balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Valeant |
Valeant Pharmaceuticals International Company probability of bankruptcy Analysis
Valeant Pharmaceuticals' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Valeant Pharmaceuticals Probability Of Bankruptcy | Over 100% |
Most of Valeant Pharmaceuticals' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Valeant Pharmaceuticals International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Valeant Pharmaceuticals probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Valeant Pharmaceuticals odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Valeant Pharmaceuticals International financial health.
Please note, there is a significant difference between Valeant Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Valeant Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Valeant Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party. The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, Valeant Pharmaceuticals International has a Probability Of Bankruptcy of 100%. This is 131.0% higher than that of the sector and 105.09% higher than that of the Probability Of Bankruptcy industry. The probability of bankruptcy for all United States stocks is 151.07% lower than that of the firm.
Valeant Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Valeant Pharmaceuticals' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Valeant Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Valeant Pharmaceuticals by comparing valuation metrics of similar companies.Valeant Pharmaceuticals is currently under evaluation in probability of bankruptcy category among related companies.
Valeant Fundamentals
| Return On Equity | -21.51 | |||
| Return On Asset | 0.69 | |||
| Profit Margin | (10.65) % | |||
| Operating Margin | 5.01 % | |||
| Current Valuation | 32.38 B | |||
| Shares Outstanding | 349.3 M | |||
| Shares Owned By Insiders | 0.30 % | |||
| Shares Owned By Institutions | 51.10 % | |||
| Number Of Shares Shorted | 14.62 M | |||
| Price To Earning | 3.43 X | |||
| Price To Book | 1.40 X | |||
| Price To Sales | 0.95 X | |||
| Revenue | 8.61 B | |||
| Gross Profit | 6.18 B | |||
| EBITDA | 3.4 B | |||
| Net Income | (917 M) | |||
| Cash And Equivalents | 909 M | |||
| Cash Per Share | 2.60 X | |||
| Total Debt | 25.27 B | |||
| Debt To Equity | 558.60 % | |||
| Current Ratio | 1.18 X | |||
| Book Value Per Share | 16.77 X | |||
| Cash Flow From Operations | 1.77 B | |||
| Short Ratio | 1.80 X | |||
| Earnings Per Share | 6.83 X | |||
| Price To Earnings To Growth | 3.05 X | |||
| Number Of Employees | 20.7 K | |||
| Beta | -0.93 | |||
| Market Capitalization | 8.17 B | |||
| Total Asset | 2.24 B | |||
| Retained Earnings | (2.75 B) | |||
| Working Capital | (23.53 M) | |||
| Current Asset | 321.63 M | |||
| Current Liabilities | 345.16 M | |||
| Z Score | 4.9 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Valeant Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Valeant Pharmaceuticals' short interest history, or implied volatility extrapolated from Valeant Pharmaceuticals options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| LTC | Litecoin | |
| STETH | Staked Ether | |
| LINK | Chainlink |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Valeant Stock
If you are still planning to invest in Valeant Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Valeant Pharmaceuticals' history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities |